Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Profound Medical Corp T.PRN

Alternate Symbol(s):  PROF

Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.


TSX:PRN - Post by User

Post by MrMugsyon May 10, 2022 3:01pm
340 Views
Post# 34671516

Quarterly ...

Quarterly ...Install base of 24 - one shy of goal ?  Lost track of where they should be.
World-wide install base is now 30.
Some lingering side-effects on the logistics side.

Pace of utilization will increase in second half.

UT SW Center - TULSA is best way to implement focal therapy and can be used to treat melignancies anywhere in the prostate.  Slow and steady at UT SW - ensure promising results - then increase usage.

Q3 - two more GE MRI sites will be added.

CAPTAIN - finish enrollment in 2nd half of 2023 and first readout of early data in Q4 of 2023.
FARP - single site level 1 study comparing similar technologies - readout July 2022.
If data outcomes match in CAPTAIN and FARP then clear superiority of TULSA in focal therapy.

AUA - Profound at meeting in a few days - more news coming before AUA meeting ???

Over 2000 procedures with over 100 physicians.
More activity coming in international markets.

CPT 1 - apply this June (on track) - effective by January 2024 if achieved.

------------------------------------------

Utilization rates - building opinion leading results - revenue coming from the 24 unit install base - should see significant improvements to utilization in the 2nd half of the year.

Funnel - 10 agreements that we have not installed - ordering new MRIs and waiting on delivery.

UT SW was a good example how things roll-out slowly - slow in the beginning - seeing cancer is not coming back - then start the ramp-up.

Sales Funnel
- imaging centers - 3 to 6 months to start producing nicely but cash only
- more focused on hospitals (coverage with c-code)

Getting $8,300 - $8,500 new per operation - over longer term, will keep our business model simple.
No push-back from our partners.

Hired Ken - making changes on the sales/marketing side - will see significant implact in the 2nd half of the year.

15 new POs (stated at Bloom Burton) but said they signed 10 agreements in this conference call - note, there are multi-site agreements in the 10 agreements.

-------------------------------

My thoughts:

First they said the bottleneck was COVID/hosipitals
Now it's the MRI installations

I'm going to say ... the bottleneck will always be reimbursement (to some degree) until they get permanent CPT 1 coverage.  As customers start to demand TULSA - that's when hospitals will get serious about MRI shortages/purchases and plans to make TULSA part of their operations.  We are counting on the industry thought leaders to get our initial install base going.  It all revolves around reimbursement and things get better the closer we get to CPT1 coverage.

Slow accumulation is/was the name of this game - all IMO.
<< Previous
Bullboard Posts
Next >>